These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7689525)

  • 1. [Benign prostatic hyperplasia--treatment with sabal fruit extract. A treatment study of 1,334 patients].
    Vahlensieck W; Völp A; Lubos W; Kuntze M
    Fortschr Med; 1993 Jun; 111(18):323-6. PubMed ID: 7689525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of benign prostatic hyperplasia. Results of a treatment study with the phytogenic combination of Sabal extract WS 1473 and Urtica extract WS 1031 in urologic specialty practices].
    Schneider HJ; Honold E; Masuhr T
    Fortschr Med; 1995 Jan; 113(3):37-40. PubMed ID: 7534258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sabal serrulata extract in the management of symptoms of prostatic hypertrophy].
    Kondás J; Philipp V; Diószeghy G
    Orv Hetil; 1997 Feb; 138(7):419-21. PubMed ID: 9091843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
    Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
    Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Drug therapy of benign prostatic hyperplasia].
    Vahlensieck W; Fabricius PG; Hell U
    Fortschr Med; 1996 Nov; 114(31):407-11. PubMed ID: 9036092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia.
    Weisser H; Tunn S; Behnke B; Krieg M
    Prostate; 1996 May; 28(5):300-6. PubMed ID: 8610056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
    Popa G; Hägele-Kaddour H; Walther C
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():103-8. PubMed ID: 16261945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year.
    Romics I; Schmitz H; Frang D
    Int Urol Nephrol; 1993; 25(6):565-9. PubMed ID: 7513678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An urodynamic study of patients with benign prostatic hypertrophy treated conservatively with phytotherapy or testosterone (author's transl)].
    Flamm J; Kiesswetter H; Englisch M
    Wien Klin Wochenschr; 1979 Sep; 91(18):622-7. PubMed ID: 90434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia.
    Takahashi S; Tajima A; Matsushima H; Kawamura T; Tominaga T; Kitamura T
    Int J Urol; 2006 Jan; 13(1):15-20. PubMed ID: 16448426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Status of phytotherapeutic drugs in treatment of benign prostatic hyperplasia].
    Dreikorn K; Schönhöfer PS
    Urologe A; 1995 Mar; 34(2):119-29. PubMed ID: 7538709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
    Yamanishi T; Yasuda K; Kamai T; Tsujii T; Sakakibara R; Uchiyama T; Yoshida K
    Int J Urol; 2004 Jul; 11(7):501-9. PubMed ID: 15242359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical effects of allylestrenol on patients with benign prostatic hyperplasia (BPH) evaluated with criteria for treatment efficacy in BPH].
    Noguchi K; Takeda M; Hosaka M; Kubota Y
    Hinyokika Kiyo; 2002 May; 48(5):269-73. PubMed ID: 12094708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of Gosyajinkigan for pollakisuria].
    Watanabe A; Akashi T; Fujiuchi Y; Mizuno I; Nagakawa O; Fuse H
    Hinyokika Kiyo; 2006 Mar; 52(3):197-201. PubMed ID: 16617873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
    Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
    Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.